{"success":true,"data":{"pressRelease":{"id":"19790","rtpr_id":"nGNX9R9wJ6","ticker":"CRSP","exchange":"NASDAQ","all_tickers":["CRSP"],"title":"CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results","author":"Globe Newswire","published_at":"2026-05-04T20:30:00.848Z","article_body":"ZUG, Switzerland and BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- CRISPR\nTherapeutics (Nasdaq: CRSP) today reported financial results for the first\nquarter ended March 31, 2026.\n\n“The first quarter reflected continued execution across CRISPR\nTherapeutics’ platform,” said Samarth Kulkarni, Ph.D., Chairman and Chief\nExecutive Officer of CRISPR Therapeutics. “We expanded zugo-cel into new\nautoimmune indications and advanced multiple in vivo liver-directed programs\ntoward the clinic, while CASGEVY continued its momentum. With a strengthened\nbalance sheet and multiple upcoming milestones, we believe 2026 will be a\ndefining year for CRISPR Therapeutics.\"\n\nRecent Highlights and Outlook\n\nHemoglobinopathies and CASGEVY® (exagamglogene autotemcel)\n* CASGEVY is approved in the U.S., Canada, the U.K., the EU, Switzerland, the\nKingdom of Saudi Arabia (KSA), the Kingdom of Bahrain, Qatar, the United Arab\nEmirates (UAE), and Kuwait for patients 12 years and older with severe sickle\ncell disease (SCD) or transfusion-dependent beta thalassemia (TDT). In total,\nthere are more than 60,000 eligible patients in these countries, including\napproximately 37,000 in North America and Europe and more than 23,000 in the\nMiddle East.\n* CASGEVY generated first quarter 2026 revenue of $43 million. More than 500\npeople globally have now initiated the CASGEVY treatment journey, reflecting\ncontinued commercial momentum.\n* Vertex has completed the U.S. regulatory submission for approval of CASGEVY\nin children ages 5 to 11 years old with SCD or TDT, extending the potential\ntreatment population to a younger age group. The U.S. Food and Drug\nAdministration (FDA) awarded a Commissioner's National Priority Voucher for\nthis pediatric submission, supporting an accelerated review timeline once\naccepted.\n* Access to CASGEVY continued to expand across key markets. Most recently, a\npricing agreement was secured for eligible patients with SCD or TDT in\nGermany, with final implementation underway. As of year-end 2025,\napproximately 90% of patients in the U.S. had reimbursed access to CASGEVY,\nwhich is also reimbursed in the U.K., Italy, Austria, Denmark, Luxembourg,\nKSA, the Kingdom of Bahrain, the UAE, and Kuwait.\n* CRISPR Therapeutics continues to advance its in vivo hematopoietic stem cell\nediting approach using lipid nanoparticle (LNP)-mediated delivery. This\napproach has the potential to expand the addressable patient populations for\nSCD and TDT.\nIn Vivo Liver Editing\n\nCRISPR Therapeutics continues to advance a diversified portfolio of in vivo\ngene editing programs leveraging its proprietary liver-directed LNP delivery\nplatform.\n* Development of CTX310®, an investigational therapy targeting\nangiopoietin-related protein 3 (ANGPTL3), is progressing in a Phase 1b\nclinical trial, where the Company is prioritizing indications in severe\nhypertriglyceridemia (sHTG) and refractory hypercholesterolemia. The Company\nrecently received FDA clearance of its Investigational New Drug (IND)\napplication, supporting expansion of the ongoing trial into the U.S. The\nCompany expects to provide an update in the second half of 2026.\n* CRISPR Therapeutics continues to advance a pipeline of preclinical in vivo\ngene editing candidates, including: * CTX460™, targeting SERPINA1 for the\ntreatment of alpha-1 antitrypsin deficiency (AATD), is the first\ninvestigational candidate generated from the Company's SyNTase™ editing\nplatform. CTX460 is currently in IND/CTA-enabling studies. The Company expects\nto initiate a clinical trial for CTX460 in mid-2026.\n* CTX340™, targeting angiotensinogen (AGT) for refractory hypertension, is\ncurrently in the IND/CTA-enabling phase. The Company expects to initiate a\nclinical trial for CTX340 in the first half of 2026.\n* CTX321™, the Company's next-generation LPA program, is progressing through\nIND/CTA-enabling studies. The candidate incorporates an optimized guide RNA\nthat delivered approximately two-fold greater potency in preclinical models,\npaired with the same LNP delivery system used previously. An Lp(a) program\nupdate is anticipated in 2026.\nsiRNA-based Programs\n\nCRISPR Therapeutics' small interfering RNA (siRNA)-based portfolio includes\nclinical-stage programs targeting cardiovascular and thromboembolic diseases,\ndeveloped in collaboration with Sirius Therapeutics.\n* CTX611 (SRSD107), a long-acting siRNA therapeutic targeting Factor XI (FXI),\nis advancing through a Phase 2 clinical trial in patients undergoing total\nknee arthroplasty (TKA). The Company expects to provide an update in the\nsecond half of 2026.\n* CTX611 has the potential to address a broad range of thromboembolic and\nclotting-related indications, including atrial fibrillation (AF), venous\nthromboembolism (VTE), ischemic stroke, cancer-associated thrombosis (CAT),\nthrombosis in chronic kidney disease (CKD), peripheral vascular disease (PVD),\nand chronic coronary artery disease (CAD), collectively representing a\nmulti-billion-dollar market opportunity. CRISPR Therapeutics is expected to\nlead global Phase 3 development, with Sirius Therapeutics overseeing\ndevelopment activities in greater China.\n* CRISPR Therapeutics has the option to nominate up to two additional siRNA\ntargets for research and development. An update is expected in 2026.\nAutoimmune Disease and Immuno-Oncology\n\nZugocabtagene geleucel (zugo-cel; formerly CTX112™) continues to advance\nacross both autoimmune disease and hematologic malignancies.\n* In autoimmune disease, zugo-cel is currently being evaluated in two ongoing\nPhase 1 basket trials: a rheumatology basket including systemic lupus\nerythematosus (SLE), systemic sclerosis (SSc), and inflammatory myositis (IM);\nand a hematology basket in immune thrombocytopenic purpura (ITP) and warm\nautoimmune hemolytic anemia (wAIHA).\n* In addition, the FDA cleared the IND application for a third Phase 1 trial\nin autoimmune neurologic diseases. The trial, which has been initiated,\nincludes progressive multiple sclerosis (PMS), neuromyelitis optica spectrum\ndisorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated\nDisease (MOGAD), N-methyl-D-aspartate receptor (NMDAR) and leucine-rich\nglioma-inactivated Protein 1 (LGI1) autoimmune encephalitis (AIE), and stiff\nperson syndrome (SPS).\n* Enrollment across the zugo-cel autoimmune clinical program continues to\nprogress, with over 14 patients dosed to date across SSc, IM, and SLE and over\n10 clinical trial sites activated globally. The previously disclosed first and\nsecond SLE patients remained in DORIS remission through Month 12 and Month 6,\nrespectively. The Company expects to provide further updates in the second\nhalf of 2026.\n* In immuno-oncology, the Phase 1/2 clinical trial of zugo-cel in B-cell\nmalignancies is ongoing, with updates anticipated in the second half of 2026.\nThe Company has also initiated a combination study evaluating zugo-cel with\npirtobrutinib in aggressive B-cell lymphomas, under the Company's existing\ncollaboration with Lilly.\n* The Company's autoimmune and immuno-oncology programs are supported by a\nwholly-owned GMP manufacturing facility in Framingham, Massachusetts. The\nfacility provides end-to-end production capabilities across the cell therapy\nportfolio, supports both clinical and future commercial supply and enables an\nindustry-leading cost of goods.\nCRISPR Therapeutics is also advancing a proprietary in vivo CAR-T platform\nwith potential applications across autoimmune disease and oncology.\n* The Company is pursuing two complementary modalities, supported by an\nantibody-conjugated LNP delivery system that enables targeted delivery to\nimmune cells: a transient, re-dosable CAR-T leveraging engineered mRNA, and a\nnon-viral, integrating CAR-T employing next-generation site-specific\nintegration technologies.\n* Preclinical studies in mice and non-human primates (NHPs) were conducted to\nevaluate a proprietary engineered transient mRNA designed to extend duration\nof expression, as well as multiple antibody binder formats directed at CD4\nand/or CD8 T-cells.\n* In mice, binders targeting both CD4+ and CD8+ T-cells, as well as binders\ntargeting CD8+ T-cells alone, demonstrated greater than 75% CAR-positive\nexpression in the respective cell types in the spleen and bone marrow.\n* In an NHP study, engineered mRNA demonstrated sustained expression for 14\ndays post dosing.\n* Furthermore, in NHPs, a proprietary antibody-conjugated LNP formulation\nencapsulating CD20-CAR transient mRNA achieved robust B-cell depletion in\nperipheral blood, spleen, and lymph nodes with three 0.5 mg/kg doses on Days\n0, 3, and 6.\nRegenerative Medicine\n* CRISPR Therapeutics continues to advance its regenerative medicine program\nin diabetes. The Company is developing CTX213™, a deviceless beta cell\nreplacement candidate for Type 1 diabetes, consisting of unencapsulated\nprecursor islet cells derived from edited induced pluripotent stem cells\n(iPSCs). CTX213 has demonstrated compelling preclinical efficacy through\ndirect administration and is progressing toward the clinic. The Company\nexpects to provide additional updates as development progresses.\nFirst Quarter 2026 Financial Results  \n* Cash Position: Cash, cash equivalents, and marketable securities were\n$2,441.8 million as of March 31, 2026, compared to $1,975.8 million as of\nDecember 31, 2025. The increase in cash was primarily driven by net proceeds\nof $585.4 million from the issuance of convertible senior notes in March 2026,\noffset by operating expenses.\n* R&D Expenses: R&D expenses were $68.6 million for the first quarter of 2026,\ncompared to $72.5 million for the first quarter of 2025. The decrease in R&D\nexpense was primarily attributable to a decrease in employee-related costs,\nincluding stock-based compensation expenses.\n* G&A Expenses: General and administrative expenses were $17.2 million for the\nfirst quarter of 2026, compared to $19.3 million for the first quarter of\n2025. The decrease in G&A expense was primarily attributable to a decrease in\nemployee-related costs.\n* Collaboration Expense: Collaboration expense, net, was $45.9 million for the\nfirst quarter of 2026, compared to $57.5 million for the first quarter of\n2025. The decrease was primarily attributable to an increase in the Company's\nshare of CASGEVY revenue.\n* Net Loss: Net loss was $122.9 million for the first quarter of 2026,\ncompared to a net loss of $136.0 million for the first quarter of 2025.\nAbout CASGEVY® (exagamglogene autotemcel [exa-cel])\n\nCASGEVY® is a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy for\neligible patients with sickle cell disease (SCD) or transfusion-dependent beta\nthalassemia (TDT), in which a patient’s own hematopoietic stem and\nprogenitor cells are edited at the erythroid specific enhancer region of the\nBCL11A gene. This edit results in the production of high levels of fetal\nhemoglobin (HbF; hemoglobin F) in red blood cells. HbF is the form of the\noxygen-carrying hemoglobin that is naturally present during fetal development,\nwhich then switches to the adult form of hemoglobin after birth. CASGEVY has\nbeen shown to reduce or eliminate VOCs for patients with SCD and transfusion\nrequirements for patients with TDT. CASGEVY is approved for eligible SCD and\nTDT patients 12 years and older by multiple regulatory bodies around the\nworld.\n\nAbout the CRISPR Therapeutics – Vertex Collaboration for CASGEVY\n\nCRISPR Therapeutics and Vertex established a strategic research collaboration\nin 2015 to discover and develop therapies leveraging CRISPR/Cas9 technology to\naddress the underlying genetic causes of human disease. CASGEVY is the first\napproved therapy to emerge from this collaboration. Under an amended\nagreement, Vertex leads global development, manufacturing, and\ncommercialization of CASGEVY, and Vertex and CRISPR Therapeutics share profits\nand program costs on a 60/40 basis. Vertex is the manufacturer and exclusive\nlicense holder of CASGEVY.\n\nAbout In Vivo Liver Editing Programs\n\nCRISPR Therapeutics has established a proprietary lipid nanoparticle (LNP)\ndelivery platform to enable gene editing in the liver using both CRISPR/Cas9\nand its novel, proprietary SyNTase™ editing technology. The Company's in\nvivo portfolio includes three cardiovascular programs: CTX310, targeting\nangiopoietin-related protein 3 (ANGPTL3), in development for heterozygous and\nhomozygous familial hypercholesterolemia, mixed dyslipidemias, and severe\nhypertriglyceridemia; CTX340, targeting angiotensinogen (AGT), in development\nfor refractory hypertension; and CTX321, targeting LPA, in development for\npatients with elevated lipoprotein(a) [Lp(a)]. In addition, the Company's\ndisclosed development candidates also include CTX460™, targeting SERPINA1\nusing SyNTase editing, for the treatment of alpha-1 antitrypsin deficiency\n(AATD).\n\nAbout Zugocabtagene Geleucel (zugo-cel; formerly CTX112)\n\nZugocabtagene geleucel (zugo-cel) is a wholly-owned, allogeneic chimeric\nantigen receptor (CAR) T cell therapy product candidate targeting Cluster of\nDifferentiation 19 (CD19), in development for both autoimmune and\nimmuno-oncology indications. The off-the-shelf therapy leverages CRISPR/Cas9\nfor targeted gene knockout and CAR insertion, enabling immune evasion and\nenhanced T effector cell potency, and is administered following a standard\nlymphodepletion regimen without the need for human leukocyte antigen (HLA)\nmatching. Zugo-cel is being investigated in ongoing clinical trials in adult\npatients with systemic lupus erythematosus (SLE), systemic sclerosis (SSc),\ninflammatory myositis (IM), immune thrombocytopenic purpura (ITP), warm\nautoimmune hemolytic anemia (wAIHA), progressive multiple sclerosis (PMS),\nneuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte\nglycoprotein antibody-associated Disease (MOGAD), N-methyl-D-aspartate\nreceptor (NMDAR) and leucine-rich glioma-inactivated Protein 1 (LGI1)\nautoimmune encephalitis (AIE), and stiff person syndrome (SPS), as well as in\nadult patients with relapsed or refractory B-cell malignancies.\n\nAbout CTX611 (SRSD107)\n\nCTX611 is a novel double-stranded, long-acting siRNA, designed to target the\nhuman coagulation factor XI, or FXI, messenger RNA and inhibit FXI protein\nexpression. Through modulation of the intrinsic coagulation pathway, CTX611 is\nintended to provide anticoagulant and antithrombotic effects with a decreased\nrisk of bleeding compared to other anti-thrombotics. Supported by clinical\nexperience conducted by Sirius Therapeutics in two Phase 1 clinical trials,\nthe Company and Sirius Therapeutics are developing CTX611 as a long-acting FXI\ninhibitor with the potential to support infrequent, including semi-annual,\nsubcutaneous administration.\n\nAbout the CRISPR Therapeutics – Sirius Therapeutics Collaboration for siRNA\n\nCRISPR Therapeutics and Sirius Therapeutics entered into a strategic\ncollaboration in 2025 to develop and commercialize siRNA therapies for\nthromboembolic disorders and other serious diseases. The lead program, CTX611,\nis a long-acting siRNA targeting FXI, which the companies will co-develop on\nan equal cost-and-profit-sharing basis. CRISPR Therapeutics will lead\ncommercialization in the U.S., while Sirius will lead commercialization in\ngreater China. The collaboration also provides CRISPR Therapeutics with the\noption to license up to two additional siRNA programs.\n\nAbout CRISPR Therapeutics\n\nCRISPR Therapeutics is a leading biopharmaceutical company focused on\ndeveloping transformative gene-based medicines for serious human diseases.\nFounded over a decade ago as an early pioneer in CRISPR/Cas9 gene editing, the\nCompany has evolved from a pioneering research-stage organization into an\nindustry leader, marking a historic milestone with the approval of CASGEVY®\n(exagamglogene autotemcel [exa-cel]), the world’s first CRISPR-based\ntherapy, for eligible patients with sickle cell disease and\ntransfusion-dependent beta thalassemia. Today, CRISPR Therapeutics is\nadvancing a broad, diversified pipeline spanning hemoglobinopathies,\ncardiovascular disease, autoimmune disease, oncology, regenerative medicine\nand rare diseases. The Company is also expanding its gene editing toolkit\nthrough SyNTase™ editing, its novel, proprietary platform designed to enable\nprecise, efficient, and scalable gene correction. To accelerate its impact,\nCRISPR Therapeutics has established strategic collaborations with leading\nbiopharmaceutical partners, including Vertex Pharmaceuticals. CRISPR\nTherapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned\nU.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in\nBoston, Massachusetts and San Francisco, California. To learn more, visit\nwww.crisprtx.com.\n\nCRISPR THERAPEUTICS® standard character mark and design logo, CTX112™,\nCTX213™, CTX310®, CTX321™, CTX340™, CTX460™, CTX611™ and SyNTase™\nare trademarks and registered trademarks of CRISPR Therapeutics AG. CASGEVY®\nand the CASGEVY logo are registered trademarks of Vertex Pharmaceuticals\nIncorporated. All other trademarks and registered trademarks are the property\nof their respective owners.\n\nCRISPR Special Note Regarding Forward-Looking Statements\n\nStatements contained in this press release regarding matters that are not\nhistorical facts are “forward-looking statements” within the meaning of\nthe Private Securities Litigation Reform Act of 1995. Because such statements\nare subject to risks and uncertainties, actual results may differ materially\nfrom those expressed or implied by such forward-looking statements. Such\nstatements include, but are not limited to, statements made by Dr. Kulkarni in\nthis press release, as well as regarding any or all of the following: (i)\nCRISPR Therapeutics preclinical studies, clinical trials and pipeline products\nand programs, including, without limitation, manufacturing capabilities,\nstatus of such studies and trials, potential expansion into new indications\nand expectations regarding data, safety and efficacy generally; (ii) data\nincluded in this press release, as well as the ability to use data from\nongoing and planned studies and clinical trials for the design and initiation\nof further studies and clinical trials; (iii) CRISPR Therapeutics strategy,\ngoals, anticipated financial performance and the sufficiency of its cash\nresources; (iv) plans and expectations for the commercialization of and\nanticipated benefits of CASGEVY, including anticipated patient access to\nCASGEVY; (v) regulatory submissions and authorizations, including timelines\nfor and expectations regarding regulatory agency decisions; (vi) the expected\nbenefits of its collaborations; and (vii) the therapeutic value, development,\nand commercial potential of gene editing technologies and therapies, including\nCRISPR/Cas9 and SyNTase, as well as other technologies. Risks that contribute\nto the uncertain nature of the forward-looking statements include, without\nlimitation, the risks and uncertainties discussed under the heading “Risk\nFactors” in its most recent annual report on Form 10-K and in any other\nsubsequent filings made by CRISPR Therapeutics with the U.S. Securities and\nExchange Commission. Existing and prospective investors are cautioned not to\nplace undue reliance on these forward-looking statements, which speak only as\nof the date they are made. We disclaim any obligation or undertaking to update\nor revise any forward-looking statements contained in this press release,\nother than to the extent required by law.\n\nThis press release also contains information regarding our industry, our\nbusiness and the markets for certain of our product candidates, including data\nregarding the estimated size of those markets, and the incidence and\nprevalence of certain medical conditions. Unless otherwise expressly stated,\nwe obtained this industry, business, market and other data from market\nresearch firms and other third parties, including medical publications,\ngovernment data and similar sources. Information that is based on estimates,\nforecasts, projections, market research or similar methodologies is inherently\nsubject to uncertainties and actual events or circumstances may differ\nmaterially from events and circumstances reflected in this information. This\npress release discusses investigational therapies and is not intended to\nconvey conclusions about efficacy or safety as to those investigational\ntherapies or uses of such investigational therapies. There is no guarantee\nthat any investigational therapy will successfully complete clinical\ndevelopment or gain approval from applicable regulatory authorities.\n\nInvestor Contact: \n+1-617-307-7503 \nir@crisprtx.com\n\nMedia Contact: \n+1-617-315-4493 \nmedia@crisprtx.com\n\nCRISPR Therapeutics AG\nCondensed Consolidated Statements of Operations\n(Unaudited, In thousands except share data and per share data)\n\n                                                       Three Months Ended March 31,                             \n                                                       2026                             2025                    \n Revenue:                                                                                                       \n Collaboration revenue                                 $      1,000                     $      —                \n Grant revenue                                                458                              865              \n Total revenue                                                1,458                            865              \n Operating expenses:                                                                                            \n Research and development                                     68,574                           72,484           \n General and administrative                                   17,183                           19,296           \n Collaboration expense, net                                   45,949                           57,509           \n Total operating expenses                                     131,706                          149,289          \n Loss from operations                                         (130,248    )                    (148,424    )    \n Total other income, net                                      8,156                            13,537           \n Net loss before income taxes                                 (122,092    )                    (134,887    )    \n Provision for income taxes                                   (839        )                    (1,109      )    \n Net loss                                                     (122,931    )                    (135,996    )    \n Foreign currency translation adjustment                      (32         )                    41               \n Unrealized (loss) gain on marketable securities              (6,730      )                    2,254            \n Comprehensive loss                                    $      (129,693    )             $      (133,701    )    \n Net loss per common share — basic                     $      (1.28       )             $      (1.58       )    \n Basic weighted-average common shares outstanding             96,051,228                       85,938,720       \n Net loss per common share — diluted                   $      (1.28       )             $      (1.58       )    \n Diluted weighted-average common shares outstanding           96,051,228                       85,938,720       \n\n\n\nCRISPR Therapeutics AG\nCondensed Consolidated Balance Sheets Data\n(Unaudited, in thousands)\n\n                               As of                                              \n                               March 31, 2026             December 31, 2025       \n Cash and cash equivalents     $         423,308          $          347,559      \n Marketable securities                   2,018,477                   1,628,269    \n Working capital                         2,312,076                   1,836,551    \n Total assets                            2,725,820                   2,265,243    \n Total shareholders' equity              1,814,556                   1,921,813    \n\n\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/5dac7d0d-131d-4047-bab7-db8e0719bf58)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX9R9wJ6","title":"CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results","author":"Globe Newswire","ticker":"CRSP","created":"2026-05-04T20:30:00.848Z","tickers":["CRSP"],"exchange":"NASDAQ","article_body":"ZUG, Switzerland and BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- CRISPR\nTherapeutics (Nasdaq: CRSP) today reported financial results for the first\nquarter ended March 31, 2026.\n\n“The first quarter reflected continued execution across CRISPR\nTherapeutics’ platform,” said Samarth Kulkarni, Ph.D., Chairman and Chief\nExecutive Officer of CRISPR Therapeutics. “We expanded zugo-cel into new\nautoimmune indications and advanced multiple in vivo liver-directed programs\ntoward the clinic, while CASGEVY continued its momentum. With a strengthened\nbalance sheet and multiple upcoming milestones, we believe 2026 will be a\ndefining year for CRISPR Therapeutics.\"\n\nRecent Highlights and Outlook\n\nHemoglobinopathies and CASGEVY® (exagamglogene autotemcel)\n* CASGEVY is approved in the U.S., Canada, the U.K., the EU, Switzerland, the\nKingdom of Saudi Arabia (KSA), the Kingdom of Bahrain, Qatar, the United Arab\nEmirates (UAE), and Kuwait for patients 12 years and older with severe sickle\ncell disease (SCD) or transfusion-dependent beta thalassemia (TDT). In total,\nthere are more than 60,000 eligible patients in these countries, including\napproximately 37,000 in North America and Europe and more than 23,000 in the\nMiddle East.\n* CASGEVY generated first quarter 2026 revenue of $43 million. More than 500\npeople globally have now initiated the CASGEVY treatment journey, reflecting\ncontinued commercial momentum.\n* Vertex has completed the U.S. regulatory submission for approval of CASGEVY\nin children ages 5 to 11 years old with SCD or TDT, extending the potential\ntreatment population to a younger age group. The U.S. Food and Drug\nAdministration (FDA) awarded a Commissioner's National Priority Voucher for\nthis pediatric submission, supporting an accelerated review timeline once\naccepted.\n* Access to CASGEVY continued to expand across key markets. Most recently, a\npricing agreement was secured for eligible patients with SCD or TDT in\nGermany, with final implementation underway. As of year-end 2025,\napproximately 90% of patients in the U.S. had reimbursed access to CASGEVY,\nwhich is also reimbursed in the U.K., Italy, Austria, Denmark, Luxembourg,\nKSA, the Kingdom of Bahrain, the UAE, and Kuwait.\n* CRISPR Therapeutics continues to advance its in vivo hematopoietic stem cell\nediting approach using lipid nanoparticle (LNP)-mediated delivery. This\napproach has the potential to expand the addressable patient populations for\nSCD and TDT.\nIn Vivo Liver Editing\n\nCRISPR Therapeutics continues to advance a diversified portfolio of in vivo\ngene editing programs leveraging its proprietary liver-directed LNP delivery\nplatform.\n* Development of CTX310®, an investigational therapy targeting\nangiopoietin-related protein 3 (ANGPTL3), is progressing in a Phase 1b\nclinical trial, where the Company is prioritizing indications in severe\nhypertriglyceridemia (sHTG) and refractory hypercholesterolemia. The Company\nrecently received FDA clearance of its Investigational New Drug (IND)\napplication, supporting expansion of the ongoing trial into the U.S. The\nCompany expects to provide an update in the second half of 2026.\n* CRISPR Therapeutics continues to advance a pipeline of preclinical in vivo\ngene editing candidates, including: * CTX460™, targeting SERPINA1 for the\ntreatment of alpha-1 antitrypsin deficiency (AATD), is the first\ninvestigational candidate generated from the Company's SyNTase™ editing\nplatform. CTX460 is currently in IND/CTA-enabling studies. The Company expects\nto initiate a clinical trial for CTX460 in mid-2026.\n* CTX340™, targeting angiotensinogen (AGT) for refractory hypertension, is\ncurrently in the IND/CTA-enabling phase. The Company expects to initiate a\nclinical trial for CTX340 in the first half of 2026.\n* CTX321™, the Company's next-generation LPA program, is progressing through\nIND/CTA-enabling studies. The candidate incorporates an optimized guide RNA\nthat delivered approximately two-fold greater potency in preclinical models,\npaired with the same LNP delivery system used previously. An Lp(a) program\nupdate is anticipated in 2026.\nsiRNA-based Programs\n\nCRISPR Therapeutics' small interfering RNA (siRNA)-based portfolio includes\nclinical-stage programs targeting cardiovascular and thromboembolic diseases,\ndeveloped in collaboration with Sirius Therapeutics.\n* CTX611 (SRSD107), a long-acting siRNA therapeutic targeting Factor XI (FXI),\nis advancing through a Phase 2 clinical trial in patients undergoing total\nknee arthroplasty (TKA). The Company expects to provide an update in the\nsecond half of 2026.\n* CTX611 has the potential to address a broad range of thromboembolic and\nclotting-related indications, including atrial fibrillation (AF), venous\nthromboembolism (VTE), ischemic stroke, cancer-associated thrombosis (CAT),\nthrombosis in chronic kidney disease (CKD), peripheral vascular disease (PVD),\nand chronic coronary artery disease (CAD), collectively representing a\nmulti-billion-dollar market opportunity. CRISPR Therapeutics is expected to\nlead global Phase 3 development, with Sirius Therapeutics overseeing\ndevelopment activities in greater China.\n* CRISPR Therapeutics has the option to nominate up to two additional siRNA\ntargets for research and development. An update is expected in 2026.\nAutoimmune Disease and Immuno-Oncology\n\nZugocabtagene geleucel (zugo-cel; formerly CTX112™) continues to advance\nacross both autoimmune disease and hematologic malignancies.\n* In autoimmune disease, zugo-cel is currently being evaluated in two ongoing\nPhase 1 basket trials: a rheumatology basket including systemic lupus\nerythematosus (SLE), systemic sclerosis (SSc), and inflammatory myositis (IM);\nand a hematology basket in immune thrombocytopenic purpura (ITP) and warm\nautoimmune hemolytic anemia (wAIHA).\n* In addition, the FDA cleared the IND application for a third Phase 1 trial\nin autoimmune neurologic diseases. The trial, which has been initiated,\nincludes progressive multiple sclerosis (PMS), neuromyelitis optica spectrum\ndisorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated\nDisease (MOGAD), N-methyl-D-aspartate receptor (NMDAR) and leucine-rich\nglioma-inactivated Protein 1 (LGI1) autoimmune encephalitis (AIE), and stiff\nperson syndrome (SPS).\n* Enrollment across the zugo-cel autoimmune clinical program continues to\nprogress, with over 14 patients dosed to date across SSc, IM, and SLE and over\n10 clinical trial sites activated globally. The previously disclosed first and\nsecond SLE patients remained in DORIS remission through Month 12 and Month 6,\nrespectively. The Company expects to provide further updates in the second\nhalf of 2026.\n* In immuno-oncology, the Phase 1/2 clinical trial of zugo-cel in B-cell\nmalignancies is ongoing, with updates anticipated in the second half of 2026.\nThe Company has also initiated a combination study evaluating zugo-cel with\npirtobrutinib in aggressive B-cell lymphomas, under the Company's existing\ncollaboration with Lilly.\n* The Company's autoimmune and immuno-oncology programs are supported by a\nwholly-owned GMP manufacturing facility in Framingham, Massachusetts. The\nfacility provides end-to-end production capabilities across the cell therapy\nportfolio, supports both clinical and future commercial supply and enables an\nindustry-leading cost of goods.\nCRISPR Therapeutics is also advancing a proprietary in vivo CAR-T platform\nwith potential applications across autoimmune disease and oncology.\n* The Company is pursuing two complementary modalities, supported by an\nantibody-conjugated LNP delivery system that enables targeted delivery to\nimmune cells: a transient, re-dosable CAR-T leveraging engineered mRNA, and a\nnon-viral, integrating CAR-T employing next-generation site-specific\nintegration technologies.\n* Preclinical studies in mice and non-human primates (NHPs) were conducted to\nevaluate a proprietary engineered transient mRNA designed to extend duration\nof expression, as well as multiple antibody binder formats directed at CD4\nand/or CD8 T-cells.\n* In mice, binders targeting both CD4+ and CD8+ T-cells, as well as binders\ntargeting CD8+ T-cells alone, demonstrated greater than 75% CAR-positive\nexpression in the respective cell types in the spleen and bone marrow.\n* In an NHP study, engineered mRNA demonstrated sustained expression for 14\ndays post dosing.\n* Furthermore, in NHPs, a proprietary antibody-conjugated LNP formulation\nencapsulating CD20-CAR transient mRNA achieved robust B-cell depletion in\nperipheral blood, spleen, and lymph nodes with three 0.5 mg/kg doses on Days\n0, 3, and 6.\nRegenerative Medicine\n* CRISPR Therapeutics continues to advance its regenerative medicine program\nin diabetes. The Company is developing CTX213™, a deviceless beta cell\nreplacement candidate for Type 1 diabetes, consisting of unencapsulated\nprecursor islet cells derived from edited induced pluripotent stem cells\n(iPSCs). CTX213 has demonstrated compelling preclinical efficacy through\ndirect administration and is progressing toward the clinic. The Company\nexpects to provide additional updates as development progresses.\nFirst Quarter 2026 Financial Results  \n* Cash Position: Cash, cash equivalents, and marketable securities were\n$2,441.8 million as of March 31, 2026, compared to $1,975.8 million as of\nDecember 31, 2025. The increase in cash was primarily driven by net proceeds\nof $585.4 million from the issuance of convertible senior notes in March 2026,\noffset by operating expenses.\n* R&D Expenses: R&D expenses were $68.6 million for the first quarter of 2026,\ncompared to $72.5 million for the first quarter of 2025. The decrease in R&D\nexpense was primarily attributable to a decrease in employee-related costs,\nincluding stock-based compensation expenses.\n* G&A Expenses: General and administrative expenses were $17.2 million for the\nfirst quarter of 2026, compared to $19.3 million for the first quarter of\n2025. The decrease in G&A expense was primarily attributable to a decrease in\nemployee-related costs.\n* Collaboration Expense: Collaboration expense, net, was $45.9 million for the\nfirst quarter of 2026, compared to $57.5 million for the first quarter of\n2025. The decrease was primarily attributable to an increase in the Company's\nshare of CASGEVY revenue.\n* Net Loss: Net loss was $122.9 million for the first quarter of 2026,\ncompared to a net loss of $136.0 million for the first quarter of 2025.\nAbout CASGEVY® (exagamglogene autotemcel [exa-cel])\n\nCASGEVY® is a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy for\neligible patients with sickle cell disease (SCD) or transfusion-dependent beta\nthalassemia (TDT), in which a patient’s own hematopoietic stem and\nprogenitor cells are edited at the erythroid specific enhancer region of the\nBCL11A gene. This edit results in the production of high levels of fetal\nhemoglobin (HbF; hemoglobin F) in red blood cells. HbF is the form of the\noxygen-carrying hemoglobin that is naturally present during fetal development,\nwhich then switches to the adult form of hemoglobin after birth. CASGEVY has\nbeen shown to reduce or eliminate VOCs for patients with SCD and transfusion\nrequirements for patients with TDT. CASGEVY is approved for eligible SCD and\nTDT patients 12 years and older by multiple regulatory bodies around the\nworld.\n\nAbout the CRISPR Therapeutics – Vertex Collaboration for CASGEVY\n\nCRISPR Therapeutics and Vertex established a strategic research collaboration\nin 2015 to discover and develop therapies leveraging CRISPR/Cas9 technology to\naddress the underlying genetic causes of human disease. CASGEVY is the first\napproved therapy to emerge from this collaboration. Under an amended\nagreement, Vertex leads global development, manufacturing, and\ncommercialization of CASGEVY, and Vertex and CRISPR Therapeutics share profits\nand program costs on a 60/40 basis. Vertex is the manufacturer and exclusive\nlicense holder of CASGEVY.\n\nAbout In Vivo Liver Editing Programs\n\nCRISPR Therapeutics has established a proprietary lipid nanoparticle (LNP)\ndelivery platform to enable gene editing in the liver using both CRISPR/Cas9\nand its novel, proprietary SyNTase™ editing technology. The Company's in\nvivo portfolio includes three cardiovascular programs: CTX310, targeting\nangiopoietin-related protein 3 (ANGPTL3), in development for heterozygous and\nhomozygous familial hypercholesterolemia, mixed dyslipidemias, and severe\nhypertriglyceridemia; CTX340, targeting angiotensinogen (AGT), in development\nfor refractory hypertension; and CTX321, targeting LPA, in development for\npatients with elevated lipoprotein(a) [Lp(a)]. In addition, the Company's\ndisclosed development candidates also include CTX460™, targeting SERPINA1\nusing SyNTase editing, for the treatment of alpha-1 antitrypsin deficiency\n(AATD).\n\nAbout Zugocabtagene Geleucel (zugo-cel; formerly CTX112)\n\nZugocabtagene geleucel (zugo-cel) is a wholly-owned, allogeneic chimeric\nantigen receptor (CAR) T cell therapy product candidate targeting Cluster of\nDifferentiation 19 (CD19), in development for both autoimmune and\nimmuno-oncology indications. The off-the-shelf therapy leverages CRISPR/Cas9\nfor targeted gene knockout and CAR insertion, enabling immune evasion and\nenhanced T effector cell potency, and is administered following a standard\nlymphodepletion regimen without the need for human leukocyte antigen (HLA)\nmatching. Zugo-cel is being investigated in ongoing clinical trials in adult\npatients with systemic lupus erythematosus (SLE), systemic sclerosis (SSc),\ninflammatory myositis (IM), immune thrombocytopenic purpura (ITP), warm\nautoimmune hemolytic anemia (wAIHA), progressive multiple sclerosis (PMS),\nneuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte\nglycoprotein antibody-associated Disease (MOGAD), N-methyl-D-aspartate\nreceptor (NMDAR) and leucine-rich glioma-inactivated Protein 1 (LGI1)\nautoimmune encephalitis (AIE), and stiff person syndrome (SPS), as well as in\nadult patients with relapsed or refractory B-cell malignancies.\n\nAbout CTX611 (SRSD107)\n\nCTX611 is a novel double-stranded, long-acting siRNA, designed to target the\nhuman coagulation factor XI, or FXI, messenger RNA and inhibit FXI protein\nexpression. Through modulation of the intrinsic coagulation pathway, CTX611 is\nintended to provide anticoagulant and antithrombotic effects with a decreased\nrisk of bleeding compared to other anti-thrombotics. Supported by clinical\nexperience conducted by Sirius Therapeutics in two Phase 1 clinical trials,\nthe Company and Sirius Therapeutics are developing CTX611 as a long-acting FXI\ninhibitor with the potential to support infrequent, including semi-annual,\nsubcutaneous administration.\n\nAbout the CRISPR Therapeutics – Sirius Therapeutics Collaboration for siRNA\n\nCRISPR Therapeutics and Sirius Therapeutics entered into a strategic\ncollaboration in 2025 to develop and commercialize siRNA therapies for\nthromboembolic disorders and other serious diseases. The lead program, CTX611,\nis a long-acting siRNA targeting FXI, which the companies will co-develop on\nan equal cost-and-profit-sharing basis. CRISPR Therapeutics will lead\ncommercialization in the U.S., while Sirius will lead commercialization in\ngreater China. The collaboration also provides CRISPR Therapeutics with the\noption to license up to two additional siRNA programs.\n\nAbout CRISPR Therapeutics\n\nCRISPR Therapeutics is a leading biopharmaceutical company focused on\ndeveloping transformative gene-based medicines for serious human diseases.\nFounded over a decade ago as an early pioneer in CRISPR/Cas9 gene editing, the\nCompany has evolved from a pioneering research-stage organization into an\nindustry leader, marking a historic milestone with the approval of CASGEVY®\n(exagamglogene autotemcel [exa-cel]), the world’s first CRISPR-based\ntherapy, for eligible patients with sickle cell disease and\ntransfusion-dependent beta thalassemia. Today, CRISPR Therapeutics is\nadvancing a broad, diversified pipeline spanning hemoglobinopathies,\ncardiovascular disease, autoimmune disease, oncology, regenerative medicine\nand rare diseases. The Company is also expanding its gene editing toolkit\nthrough SyNTase™ editing, its novel, proprietary platform designed to enable\nprecise, efficient, and scalable gene correction. To accelerate its impact,\nCRISPR Therapeutics has established strategic collaborations with leading\nbiopharmaceutical partners, including Vertex Pharmaceuticals. CRISPR\nTherapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned\nU.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in\nBoston, Massachusetts and San Francisco, California. To learn more, visit\nwww.crisprtx.com.\n\nCRISPR THERAPEUTICS® standard character mark and design logo, CTX112™,\nCTX213™, CTX310®, CTX321™, CTX340™, CTX460™, CTX611™ and SyNTase™\nare trademarks and registered trademarks of CRISPR Therapeutics AG. CASGEVY®\nand the CASGEVY logo are registered trademarks of Vertex Pharmaceuticals\nIncorporated. All other trademarks and registered trademarks are the property\nof their respective owners.\n\nCRISPR Special Note Regarding Forward-Looking Statements\n\nStatements contained in this press release regarding matters that are not\nhistorical facts are “forward-looking statements” within the meaning of\nthe Private Securities Litigation Reform Act of 1995. Because such statements\nare subject to risks and uncertainties, actual results may differ materially\nfrom those expressed or implied by such forward-looking statements. Such\nstatements include, but are not limited to, statements made by Dr. Kulkarni in\nthis press release, as well as regarding any or all of the following: (i)\nCRISPR Therapeutics preclinical studies, clinical trials and pipeline products\nand programs, including, without limitation, manufacturing capabilities,\nstatus of such studies and trials, potential expansion into new indications\nand expectations regarding data, safety and efficacy generally; (ii) data\nincluded in this press release, as well as the ability to use data from\nongoing and planned studies and clinical trials for the design and initiation\nof further studies and clinical trials; (iii) CRISPR Therapeutics strategy,\ngoals, anticipated financial performance and the sufficiency of its cash\nresources; (iv) plans and expectations for the commercialization of and\nanticipated benefits of CASGEVY, including anticipated patient access to\nCASGEVY; (v) regulatory submissions and authorizations, including timelines\nfor and expectations regarding regulatory agency decisions; (vi) the expected\nbenefits of its collaborations; and (vii) the therapeutic value, development,\nand commercial potential of gene editing technologies and therapies, including\nCRISPR/Cas9 and SyNTase, as well as other technologies. Risks that contribute\nto the uncertain nature of the forward-looking statements include, without\nlimitation, the risks and uncertainties discussed under the heading “Risk\nFactors” in its most recent annual report on Form 10-K and in any other\nsubsequent filings made by CRISPR Therapeutics with the U.S. Securities and\nExchange Commission. Existing and prospective investors are cautioned not to\nplace undue reliance on these forward-looking statements, which speak only as\nof the date they are made. We disclaim any obligation or undertaking to update\nor revise any forward-looking statements contained in this press release,\nother than to the extent required by law.\n\nThis press release also contains information regarding our industry, our\nbusiness and the markets for certain of our product candidates, including data\nregarding the estimated size of those markets, and the incidence and\nprevalence of certain medical conditions. Unless otherwise expressly stated,\nwe obtained this industry, business, market and other data from market\nresearch firms and other third parties, including medical publications,\ngovernment data and similar sources. Information that is based on estimates,\nforecasts, projections, market research or similar methodologies is inherently\nsubject to uncertainties and actual events or circumstances may differ\nmaterially from events and circumstances reflected in this information. This\npress release discusses investigational therapies and is not intended to\nconvey conclusions about efficacy or safety as to those investigational\ntherapies or uses of such investigational therapies. There is no guarantee\nthat any investigational therapy will successfully complete clinical\ndevelopment or gain approval from applicable regulatory authorities.\n\nInvestor Contact: \n+1-617-307-7503 \nir@crisprtx.com\n\nMedia Contact: \n+1-617-315-4493 \nmedia@crisprtx.com\n\nCRISPR Therapeutics AG\nCondensed Consolidated Statements of Operations\n(Unaudited, In thousands except share data and per share data)\n\n                                                       Three Months Ended March 31,                             \n                                                       2026                             2025                    \n Revenue:                                                                                                       \n Collaboration revenue                                 $      1,000                     $      —                \n Grant revenue                                                458                              865              \n Total revenue                                                1,458                            865              \n Operating expenses:                                                                                            \n Research and development                                     68,574                           72,484           \n General and administrative                                   17,183                           19,296           \n Collaboration expense, net                                   45,949                           57,509           \n Total operating expenses                                     131,706                          149,289          \n Loss from operations                                         (130,248    )                    (148,424    )    \n Total other income, net                                      8,156                            13,537           \n Net loss before income taxes                                 (122,092    )                    (134,887    )    \n Provision for income taxes                                   (839        )                    (1,109      )    \n Net loss                                                     (122,931    )                    (135,996    )    \n Foreign currency translation adjustment                      (32         )                    41               \n Unrealized (loss) gain on marketable securities              (6,730      )                    2,254            \n Comprehensive loss                                    $      (129,693    )             $      (133,701    )    \n Net loss per common share — basic                     $      (1.28       )             $      (1.58       )    \n Basic weighted-average common shares outstanding             96,051,228                       85,938,720       \n Net loss per common share — diluted                   $      (1.28       )             $      (1.58       )    \n Diluted weighted-average common shares outstanding           96,051,228                       85,938,720       \n\n\n\nCRISPR Therapeutics AG\nCondensed Consolidated Balance Sheets Data\n(Unaudited, in thousands)\n\n                               As of                                              \n                               March 31, 2026             December 31, 2025       \n Cash and cash equivalents     $         423,308          $          347,559      \n Marketable securities                   2,018,477                   1,628,269    \n Working capital                         2,312,076                   1,836,551    \n Total assets                            2,725,820                   2,265,243    \n Total shareholders' equity              1,814,556                   1,921,813    \n\n\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/5dac7d0d-131d-4047-bab7-db8e0719bf58)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-04T20:30:00.928965382Z","server_sent_at_ms":1777926600928},"received_at":"2026-05-04T20:30:01.010Z","source_url":"https://www.globenewswire.com/news-release/2026/02/12/3237711/0/en/crispr-therapeutics-provides-business-update-and-reports-fourth-quarter-and-full-year-2025-financial-results.html"},"analysis":{"id":"14492","press_release_id":"19790","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"earnings","narrative":"CRISPR Therapeutics reported Q1 2026 financial results featuring a strengthened balance sheet with $2.44 billion in cash, driven by $585.4 million in convertible note proceeds. Commercial momentum continued with CASGEVY generating $43 million in product revenue, as over 500 patients globally have initiated treatment.\n\nPipeline advancement included FDA IND clearance for zugo-cel in autoimmune neurologic diseases and the progression of multiple in vivo liver programs. The company expects to initiate clinical trials for CTX340 (hypertension) in the first half of 2026 and CTX460 (AATD) by mid-2026.\n\nOperating discipline was evident as R&D expenses decreased to $68.6 million, contributing to a net loss of $122.9 million, an improvement from the prior year. Management emphasized that the strengthened financial position and upcoming milestones set the stage for a defining 2026.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"CASGEVY sales ramp and a $2.4B cash pile de-risk the biotech story as pipeline milestones loom."},"keyFigures":{"drugName":"CASGEVY","customDimensions":{"net_loss_usd":122900000,"rnd_expenses_usd":68600000,"casgevy_product_revenue":43000000,"convertible_notes_proceeds_usd":585400000}},"quotedText":"With a strengthened balance sheet and multiple upcoming milestones, we believe 2026 will be a defining year for CRISPR Therapeutics.","namedEntities":{"people":[{"name":"Samarth Kulkarni","role":"Chairman and Chief Executive Officer"}],"products":["CASGEVY","Zugo-cel","CTX310","CTX340","CTX460","CTX321","CTX611","CTX213"],"companies":[{"name":"Vertex Pharmaceuticals","relationship":"partner"},{"name":"Sirius Therapeutics","relationship":"partner"},{"name":"Lilly","relationship":"partner"}],"dollarAmounts":[{"amount":"$43 million","context":"CASGEVY first quarter 2026 revenue"},{"amount":"$2,441.8 million","context":"Cash, cash equivalents, and marketable securities as of March 31, 2026"},{"amount":"$585.4 million","context":"Net proceeds from issuance of convertible senior notes"},{"amount":"$122.9 million","context":"Net loss for the first quarter of 2026"},{"amount":"$68.6 million","context":"R&D expenses for the first quarter of 2026"}]},"materialImpact":{"score":3,"reasoning":"CRISPR reported solid commercial execution with CASGEVY generating $43 million in product revenue and over 500 treatment initiations. The balance sheet was significantly strengthened to $2.44 billion via a convertible notes offering, and multiple pipeline programs (CTX310, CTX340, CTX460, zugo-cel) achieved key clinical milestones or IND clearances."},"tickerRelevance":{"others":[],"primary":"CRSP"},"globalImportance":35,"audienceRelevance":55,"eventTypeSecondary":["clinical_trial","offering"],"importanceComponents":{"tickerTier":"mid-large_cap_biotech","eventGravity":"earnings_and_milestones","sectorWeight":"biotech","cashPositionStrengthening":true}},"event_type":"earnings","event_type_secondary":["clinical_trial","offering"],"sentiment":"bullish","material_impact_score":3,"narrative":"CRISPR Therapeutics reported Q1 2026 financial results featuring a strengthened balance sheet with $2.44 billion in cash, driven by $585.4 million in convertible note proceeds. Commercial momentum continued with CASGEVY generating $43 million in product revenue, as over 500 patients globally have initiated treatment.\n\nPipeline advancement included FDA IND clearance for zugo-cel in autoimmune neurologic diseases and the progression of multiple in vivo liver programs. The company expects to initiate clinical trials for CTX340 (hypertension) in the first half of 2026 and CTX460 (AATD) by mid-2026.\n\nOperating discipline was evident as R&D expenses decreased to $68.6 million, contributing to a net loss of $122.9 million, an improvement from the prior year. Management emphasized that the strengthened financial position and upcoming milestones set the stage for a defining 2026.","key_figures":{"drugName":"CASGEVY","customDimensions":{"net_loss_usd":122900000,"rnd_expenses_usd":68600000,"casgevy_product_revenue":43000000,"convertible_notes_proceeds_usd":585400000}},"named_entities":{"people":[{"name":"Samarth Kulkarni","role":"Chairman and Chief Executive Officer"}],"products":["CASGEVY","Zugo-cel","CTX310","CTX340","CTX460","CTX321","CTX611","CTX213"],"companies":[{"name":"Vertex Pharmaceuticals","relationship":"partner"},{"name":"Sirius Therapeutics","relationship":"partner"},{"name":"Lilly","relationship":"partner"}],"dollarAmounts":[{"amount":"$43 million","context":"CASGEVY first quarter 2026 revenue"},{"amount":"$2,441.8 million","context":"Cash, cash equivalents, and marketable securities as of March 31, 2026"},{"amount":"$585.4 million","context":"Net proceeds from issuance of convertible senior notes"},{"amount":"$122.9 million","context":"Net loss for the first quarter of 2026"},{"amount":"$68.6 million","context":"R&D expenses for the first quarter of 2026"}]},"model_name":"glm-4.7","prompt_hash":"sha256:a2703c5a1b5285fe","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-05-04T21:31:55.280Z","global_importance":35,"audience_relevance":55,"importance_components":{"tickerTier":"mid-large_cap_biotech","eventGravity":"earnings_and_milestones","sectorWeight":"biotech","cashPositionStrengthening":true}},"durationMs":64833,"modelName":"glm-4.7"}}